Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Ahead-of-print articles

Page Path
HOME > Articles and issues > Ahead-of-print articles
1 Ahead-of-print articles
Filter
Filter
Article category

Articles in E-pub version are posted online ahead of regular printed publication.

Case Report
Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report
Pramod Kumar, Pradeep Krishna, Rohit Maidur, Naveen Chandrashekhar, Suresh Raghavaiah
Received June 14, 2024  Accepted September 26, 2024  Published online November 5, 2024  
DOI: https://doi.org/10.17998/jlc.2024.09.26    [Accepted]
  • 335 Views
  • 59 Downloads
AbstractAbstract PDF
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST criteria. The treatment duration is until disease progression or unacceptable side effects occur. Long-term continuation can cause potential toxicities and a substantial financial burden, making early treatment discontinuation a viable option. This report describes durable CR after discontinuing atezo-bev treatment in three patients with HCC and PVTT.
Close layer

JLC : Journal of Liver Cancer
TOP